UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 28, 2015

CORINDUS VASCULAR ROBOTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

309 Waverley Oaks Rd., Suite 105

Waltham, MA 02452

(Address of Principal Executive Office) (Zip Code)

Registrant’s telephone number, including area code: (508) 653-3335

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

Item 1.01 Entry into a Material Definitive Agreement.

On May 28, 2015, Corindus Vascular Robotics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cowen and Company, LLC and Stifel, Nicolaus & Company, Incorporated, as underwriters and representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”) in connection with the underwritten public offering of 11,000,000 shares of the Company’s common stock, par value $0.0001 per share at a public offering price of $3.80 per share (the “Offering”). Underwriting Agreement provided the Underwriters a 30-day option to purchase up to 1,650,000 additional shares of the Company’s common stock at the public offering price, which was fully exercised by the Underwriters prior to the closing of the Offering. The Offering closed on June 3, 2015 and the Company estimates that the net proceeds received in the Offering were approximately $44.7 million after deducting underwriting discounts and commissions and other offering expenses payable by the Company.

The Underwriting Agreement contains customary representations and warranties and covenants of the Company and other customary obligations of the parties and termination provisions. The Underwriting Agreement also provides for the indemnification by the Company of the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended. Furthermore, the Company has agreed with the Underwriters not to offer or sell any shares of its common stock (or securities convertible into or exchangeable for common stock), subject to certain exceptions, for a period of 90 days after the date of the Underwriting Agreement without the prior written consent of the Representatives.

The Offering was made pursuant to an effective Registration Statement (Registration No. 333-204037) on Form S-1 previously filed with the Securities and Exchange Commission (the “SEC”) and a prospectus thereunder.

In connection with the Offering, the Company’s common stock was approved for listing on the NYSE MKT. Trading commenced on Friday, May 29, 2015, under the symbol “CVRS.”

The foregoing description of the Underwriting Agreement is qualified in its entirety by reference to the Underwriting Agreement, the form of which was filed with the SEC as Exhibit 1.1 to the First Amendment to Form S-1 Registration Statement on May 26, 2015, which Exhibit is incorporated herein by reference.

Item 8.01. Other Events.

On May 28, 2015, the Company issued a press release announcing that the common stock to be sold in the Offering would be sold at a public offering price of $3.80 per share. A copy of this press release is attached hereto as Exhibit 99.1.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.